Association Between Malignancy and Topical Use of Pimecrolimus. - Wikidata - awgldk - TriplyDB

Association Between Malignancy and Topical Use of Pimecrolimus.

Association Between Malignancy and Topical Use of Pimecrolimus.

http://www.wikidata.org/entity/Q35733343

about

Current Management of Pediatric Vitiligo.Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis.Acute Pustular Dermatosis, Following Topical Treatment With Pimecrolimus, in a Child Affected With Atopic and Contact Hand Dermatitis Hand dermatitis: a review of clinical features, prevention and treatment.Variations in risk of asthma and seasonal allergies between early- and late-onset pediatric atopic dermatitis: A cohort study.Advances in therapeutic strategies for the treatment of pruritus.Treatment of allergic children - Where is the progress (for the practicing allergist)?Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.Topical calcineurin inhibitors in eczema and cancer association: A cohort study.Pharmacokinetic Profile, Safety, and Tolerability of Crisaborole Topical Ointment, 2% in Adolescents with Atopic Dermatitis: An Open-Label Phase 2a Study.Atopic Dermatitis Disease Complications.Atopic Dermatitis: Disease Background and Risk Factors.The safety of treatments used in pyoderma gangrenosum.Risk of melanocytic nevi and nonmelanoma skin cancer in children after allogeneic hematopoietic stem cell transplantation.A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study).

P2860

Q34478386-5D3701A9-2ACB-4071-82FF-5743AB11E8BB Q36042131-85C68583-FE15-4FAF-B65F-CF3182507C6B Q36652818-249B933A-29D4-4433-B358-B458E1E7CB08 Q38446594-94E3DAFD-EBEE-442F-AF0C-64AA9A9C3ED6 Q38619479-528359BD-1354-459D-A26E-F77DF71F179F Q38656850-8DCE817D-8768-45D3-B1A9-28CDAD5596CD Q38809512-8DFF65F6-E875-4D34-8498-02AA69E00619 Q38860798-8E672518-B060-4978-90E0-B1CE0ED96F79 Q39859545-126D94D9-81F7-4EF0-BD3D-B256812E3E8C Q46098786-67D72353-9BD5-4895-A3A8-52C8CA1968AA Q47602719-52373E14-CF6B-44AF-ADA4-59DBF903869D Q47602738-0B67799C-4F74-44C2-8972-E24C1140A40A Q47641664-09383A69-F808-4340-93E6-44B10CBFAB21 Q50756733-66A54052-ECB8-4785-9159-72AAF5AEE778 Q52646026-6D8F7CA5-24BD-443D-8D78-F6A67E034D75

P2860

Association Between Malignancy and Topical Use of Pimecrolimus.

http://www.wikidata.org/entity/Q35733343

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Association Between Malignancy and Topical Use of Pimecrolimus.

@ast

Association Between Malignancy and Topical Use of Pimecrolimus.

@en

type

label

Association Between Malignancy and Topical Use of Pimecrolimus.

@ast

Association Between Malignancy and Topical Use of Pimecrolimus.

@en

prefLabel

Association Between Malignancy and Topical Use of Pimecrolimus.

@ast

Association Between Malignancy and Topical Use of Pimecrolimus.

@en

P1433

Q35733343-5AF94440-C330-4878-AD75-61B99E4FC589

P1476

Q35733343-378A19EE-FC3A-4DED-AAC1-1AE35727162B

P2093

Q35733343-1D8ED7A1-34BD-437B-AC75-8894C9E6BF00

Q35733343-883455EF-9C55-4088-9169-36E88C845154

Q35733343-8AC41A40-A42A-435C-9FBF-059ADB48C124

Q35733343-B4D14210-292F-40A3-B632-38E1C7DC5491

Q35733343-E45BA88C-E953-493E-8752-DC76E8B497D9

P2860

Q35733343-03D3A6C7-F1A9-47BB-8D35-2257EFAABFD2

Q35733343-33058D22-9827-46D9-9772-25B72BA81693

Q35733343-393E645E-7E4D-4917-B48B-6D009F4906C3

Q35733343-3F17383D-0221-460B-989C-92D9DE11C7C6

Q35733343-405C8663-D787-479C-B99B-BFB89B420C33

Q35733343-4DDDF946-73BB-431B-9BC6-D55D1E842758

Q35733343-526DD3EF-4647-4B18-A76E-C7BEF0E2BDEC

Q35733343-59D21846-CF08-4263-8F7B-C48EF15C63B3

Q35733343-5E9D0EB9-C7CD-4A7B-8A5E-2F34C03BA6A0

Q35733343-63678E9E-A6F1-480D-A975-B32EBEDB9DEB

P304

Q35733343-2261813A-FE04-47D0-AF10-2147E7B07355

P31

Q35733343-64FCFC2E-B4EA-4971-9510-27F14D6AC3D0

P356

Q35733343-F59932C4-956C-4D42-88C8-DF63A0B0B6D0

P407

Q35733343-7261C8E0-3910-4164-8577-2F1683D19BE2

P433

Q35733343-B6D81898-C588-40D6-B8DD-CE0C47474085

P478

Q35733343-B3C08946-5B44-455C-9136-67B139D72698

P50

Q35733343-D462F703-3F95-472E-A7A8-35BF4A52AAB9

P577

Q35733343-F7C7B12F-3B25-4A2C-B058-F24424ADCF12

P698

Q35733343-9E59AF54-9E75-4004-BD53-B056201C4E5F

P932

Q35733343-02FCB16C-6260-44F0-9CA0-ED3D7EBA1749

P356

JAMADERMATOL.2014.4305

P1433

JAMA Dermatology

P1476

Association Between Malignancy and Topical Use of Pimecrolimus.

@en

P2093

David J Margolis

http://www.w3.org/2001/XMLSchema#string

Denise Raimondo

http://www.w3.org/2001/XMLSchema#string

Joy Wan

http://www.w3.org/2001/XMLSchema#string

Ole J Hoffstad

http://www.w3.org/2001/XMLSchema#string

Warren B Bilker

http://www.w3.org/2001/XMLSchema#string

P2860

Skin cancer in solid organ transplant recipients: advances in therapy and management: part I. Epidemiology of skin cancer in solid organ transplant recipients.

The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions.

Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis.

Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management.

Skin cancers after organ transplantation.

Persistence of mild to moderate atopic dermatitis.

The persistence of atopic dermatitis and filaggrin (FLG) mutations in a US longitudinal cohort

Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice.

Risk of lymphoma subtypes after solid organ transplantation in the United States.

Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma.

P304

594-599

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMADERMATOL.2014.4305

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

151

http://www.w3.org/2001/XMLSchema#string

P50

Katrina Abuabara

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25692459

http://www.w3.org/2001/XMLSchema#string

P932

4465068

http://www.w3.org/2001/XMLSchema#string